AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22814125 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (CT) (n=91)
Number of subjects: 192
Study 22814125 — intervention group
Group type: EXPERIMENTAL
Intervention: bPImono
Number of subjects: 192
Study 22814125 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (CT)
Number of subjects: 192
Study 19397632 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized zirconia abutments
Number of subjects: 22
Study 19397632 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized titanium abutments
Number of subjects: 22
Study 19397632 — intervention group
Group type: COMPARATOR
Intervention: Both zirconia and titanium abutments
Number of subjects: 22
Study 17605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-ecologically based lifestyle intervention (2 face-to-face sessions, 3 follow-up calls, 3 newsletters)
Number of subjects: 200
Study 17605558 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 15050905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) for 2-3 years
Number of subjects: 347
Study 15050905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 12202466 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg or more)
Number of subjects: 8
Study 12202466 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg daily)
Number of subjects: 8
Study 12202466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9789483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 0
Study 9789483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.8 mg daily
Number of subjects: 0
Study 9789483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (any dose)
Number of subjects: 0
Study 9789483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study 7502628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) for up to 12 months followed by combination therapy with HU and human recombinant erythropoietin (rHuEpo; 400 U/kg/week i.v.) for 3-4 weeks.
Number of subjects: 7
Study 7502628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with HU and rHuEpo
Number of subjects: 7
Study 7502628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) alone after rHuEpo withdrawal
Number of subjects: 7
Study 2019880 — intervention group
Group type: COMPARATOR
Intervention: MnCl2 (control)
Number of subjects: 0
Study 2019880 — intervention group
Group type: EXPERIMENTAL
Intervention: Lettuce
Number of subjects: 0
Study 2019880 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 0
Study 2019880 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat
Number of subjects: 0
Study 2019880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seeds
Number of subjects: 0
Study 2019880 — intervention group
Group type: EXPERIMENTAL
Intervention: All food sources
Number of subjects: 0
Study 7046777 — intervention group
Group type: EXPERIMENTAL
Intervention: Xipamide 10 mg daily
Number of subjects: 14
Study 7046777 — intervention group
Group type: EXPERIMENTAL
Intervention: Xipamide 20 mg daily
Number of subjects: 14
Study 7046777 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide 0.5 mg daily
Number of subjects: 14
Study 31277823 — intervention group
Group type: EXPERIMENTAL
Intervention: LL→PP (Cladribine after placebo)
Number of subjects: 0
Study 31277823 — intervention group
Group type: COMPARATOR
Intervention: PP→PP (placebo to placebo)
Number of subjects: 0
Study 28088203 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 1056
Study 28088203 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 1056
Study 28088203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1056
Study 26068613 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 123
Study 26068613 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Number of subjects: 123
Study 23620599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin inhalation
Number of subjects: 0
Study 23620599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23181985 — intervention group
Group type: EXPERIMENTAL
Intervention: text4baby intervention
Number of subjects: 123
Study 23181985 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 123
Study 20004779 — intervention group
Group type: EXPERIMENTAL
Intervention: Early therapy with inhaled corticosteroid (ICS) budesonide for 2 years
Number of subjects: 90
Study 20004779 — intervention group
Group type: COMPARATOR
Intervention: Delayed therapy with inhaled corticosteroid (ICS) budesonide after 2 years of terbutaline treatment
Number of subjects: 90
Study 17312235 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ropivacaine and clonidine (block group)
Number of subjects: 70
Study 17312235 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 70
Study 15257093 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NAME treatment
Number of subjects: 28
Study 11251000 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel (AT)
Number of subjects: 267
Study 11251000 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 267
Study 9586791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic phosphorus at 45 mmol/d
Number of subjects: 7
Study 9586791 — intervention group
Group type: COMPARATOR
Intervention: Inorganic phosphorus at 15 mmol/d
Number of subjects: 7
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Written consent
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information without obligatory signing
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal consent
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: No consent sought
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Full information on all aspects of the trial
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on proposed treatment arm only
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealing inclusion in an RCT
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical origin of clinicians
Number of subjects: 60
Study 7946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of trial (supportive care vs curative/palliative)
Number of subjects: 60
Study 1762806 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of epidural morphine
Number of subjects: 28
Study 1762806 — intervention group
Group type: COMPARATOR
Intervention: Repeated bolus doses of epidural morphine
Number of subjects: 28
Study 6895739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried skimmed milk (DSM)
Number of subjects: 600
Study 6895739 — intervention group
Group type: COMPARATOR
Intervention: Local beans (Control)
Number of subjects: 600
Study 30246463 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Product Request (DPR)
Number of subjects: 220
Study 30246463 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-Based Request (SBR)
Number of subjects: 220
Study 30246463 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall handling of nonhealing mouth ulcer consultations
Number of subjects: 220
Study 28506775 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised (center‐based) exercise program
Number of subjects: 98
Study 28506775 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised (home‐based) exercise program
Number of subjects: 98
Study 26427111 — intervention group
Group type: EXPERIMENTAL
Intervention: Huqian Wan
Number of subjects: 100
Study 26427111 — intervention group
Group type: COMPARATOR
Intervention: Votalin, 75 mg, once a day for 8 weeks
Number of subjects: 100
Study 23568432 — intervention group
Group type: EXPERIMENTAL
Intervention: HME filters
Number of subjects: 0
Study 23568432 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifiers (HHs)
Number of subjects: 0
Study 20675057 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg/day of progesterone
Number of subjects: 64
Study 20675057 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg/day of progesterone
Number of subjects: 64
Study 20675057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19009458 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day of vitamin C for 14 days
Number of subjects: 24
Study 19009458 — intervention group
Group type: COMPARATOR
Intervention: 125 mg ascorbate after a 7-14 day non-intervention period
Number of subjects: 24
Study 19009458 — intervention group
Group type: COMPARATOR
Intervention: 250 mg ascorbate dosage regimen
Number of subjects: 24
Study 19009458 — intervention group
Group type: COMPARATOR
Intervention: 500 mg ascorbate dosage regimen
Number of subjects: 24
Study 19009458 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg ascorbate dosage regimen
Number of subjects: 24
Study 17550494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Continence Advisor (NCA) group (N = 73)
Number of subjects: 205
Study 17550494 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogynaecologist (UG) group (N = 72)
Number of subjects: 205
Study 17550494 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic colposuspension (LC) group
Number of subjects: 205
Study 17550494 — intervention group
Group type: COMPARATOR
Intervention: Open colposuspension (OC) group
Number of subjects: 205
Study 14759623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 32
Study 14759623 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (400 microg)
Number of subjects: 32
Study 11590482 — intervention group
Group type: EXPERIMENTAL
Intervention: VC-1500 (1500 mg/day Vitamin C)
Number of subjects: 45
Study 11590482 — intervention group
Group type: COMPARATOR
Intervention: VC-500 (500 mg/day Vitamin C)
Number of subjects: 45
Study 11590482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 45
Study 9533371 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg of Curosurf via dual-lumen endotracheal tube
Number of subjects: 198
Study 9533371 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/kg of Curosurf via bolus instillation
Number of subjects: 198
Study 8307216 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 50
Study 8307216 — intervention group
Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 50
Study 2962478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator, percutaneous coronary angioplasty, or both
Number of subjects: 50
Study 31455229 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 4816
Study 31455229 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identified barriers to care
Number of subjects: 4816
Study 31455229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health score
Number of subjects: 4816
Study 31455229 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 4816
Study 28341958 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin (DP) - docetaxel (35 mg/m2)/cisplatin (30 mg/m2) iv on days 1 and 8, every 3 weeks.
Number of subjects: 99
Study 28341958 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GP) - gemcitabine (1000 mg/m2)/cisplatin (30 mg/m2) iv on days 1 and 8, every 3 weeks.
Number of subjects: 99
Study 28341958 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GP)
Number of subjects: 99
Study 28341958 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin (DP)
Number of subjects: 99
Study 25588168 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvard TEMP
Number of subjects: 21
Study 25588168 — intervention group
Group type: EXPERIMENTAL
Intervention: Improv
Number of subjects: 21
Study 25588168 — intervention group
Group type: EXPERIMENTAL
Intervention: Durelon
Number of subjects: 21
Study 25588168 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-accelerated crown remover
Number of subjects: 21
Study 25588168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement type
Number of subjects: 21
Study 25588168 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of activations
Number of subjects: 21
Study 22271372 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (300 mg/day)
Number of subjects: 60
Study 22271372 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (10 mg/day)
Number of subjects: 60
Study 22271372 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (300 mg/day) + Amitriptyline (10 mg/day)
Number of subjects: 60
Study 22271372 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 60
Study 21693570 — intervention group
Group type: EXPERIMENTAL
Intervention: DM self management programme (experimental group) - six sessions of weekly course
Number of subjects: 157
Study 21693570 — intervention group
Group type: EXPERIMENTAL
Intervention: DM self management programme (experimental group)
Number of subjects: 157
Study 21693570 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 18637168 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised 10-year CVD risk estimate and brief lifestyle advice intervention targeting physical activity, diet, and smoking cessation
Number of subjects: 200
Study 18637168 — intervention group
Group type: COMPARATOR
Intervention: Numerical CVD risk factor values (systolic blood pressure, LDL cholesterol, fasting glucose) and no lifestyle advice intervention
Number of subjects: 200
Study 18637168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (personalised risk estimate and lifestyle advice)
Number of subjects: 200
Study 18637168 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 200
Study 16247249 — intervention group
Group type: EXPERIMENTAL
Intervention: R126638 100 mg
Number of subjects: 16
Study 16247249 — intervention group
Group type: EXPERIMENTAL
Intervention: R126638 200 mg
Number of subjects: 16
Study 16247249 — intervention group
Group type: EXPERIMENTAL
Intervention: R126638 (both dosages)
Number of subjects: 16
Study 12970133 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 110
Study 12970133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11115305 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.10 mg/kg per dose)
Number of subjects: 39
Study 11115305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9376575 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 318
Study 9376575 — intervention group
Group type: COMPARATOR
Intervention: Control (daunomycin-cytosine arabinoside)
Number of subjects: 318
Study 1622977 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled white rice (25 g carbohydrate)
Number of subjects: 7
Study 1622977 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled white rice (50 g carbohydrate)
Number of subjects: 7
Study 1622977 — intervention group
Group type: COMPARATOR
Intervention: White bread (25 g carbohydrate)
Number of subjects: 7
Study 1622977 — intervention group
Group type: COMPARATOR
Intervention: White bread (50 g carbohydrate)
Number of subjects: 7
Study 3924748 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (0.35 mg/kg)
Number of subjects: 10
Study 3924748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30189025 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm of a randomized clinical trial
Number of subjects: 125
Study 30189025 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and communication intervention
Number of subjects: 125
Study 30189025 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling intervention
Number of subjects: 125
Study 30291940 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (7.5 mg)
Number of subjects: 77
Study 30291940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 77
Study 26378963 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication facilitator intervention
Number of subjects: 168
Study 26378963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no communication facilitator)
Number of subjects: 168
Study 26378963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 24848838 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative breast MRI
Number of subjects: 348
Study 24848838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative breast MRI)
Number of subjects: 348
Study 22356757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP) via Foley catheter with 4 mL of inseminate
Number of subjects: 120
Study 22356757 — intervention group
Group type: COMPARATOR
Intervention: Standard intrauterine insemination (IUI) with 0.5 mL of inseminate
Number of subjects: 120
Study 20515286 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro diagnostic device (IVD) based on a biomarker
Number of subjects: 0
Study 20515286 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 18058480 — intervention group
Group type: EXPERIMENTAL
Intervention: ARBs
Number of subjects: 347
Study 18058480 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 347
Study 18058480 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBs
Number of subjects: 347
Study 18058480 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 347
Study 18058480 — intervention group
Group type: EXPERIMENTAL
Intervention: diuretics
Number of subjects: 347
Study 18058480 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine
Number of subjects: 347
Study 16084434 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium 99m sestamibi/fluorine 18 fluorodeoxyglucose dual‐isotope simultaneous acquisition (DISA)
Number of subjects: 42
Study 16084434 — intervention group
Group type: COMPARATOR
Intervention: Thallium 201 single photon emission computed tomography (SPECT)
Number of subjects: 42
Study 12135223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal growth restriction (n=13)
Number of subjects: 63
Study 12135223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia (n=26)
Number of subjects: 63
Study 12135223 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant controls (n=24)
Number of subjects: 63
Study 10089853 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing therapy
Number of subjects: 0
Study 10089853 — intervention group
Group type: COMPARATOR
Intervention: No pacing therapy (control)
Number of subjects: 0
Study 10089853 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing therapy (with ICD)
Number of subjects: 0
Study 10089853 — intervention group
Group type: COMPARATOR
Intervention: No pacing (control)
Number of subjects: 0
Study 7475182 — intervention group
Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (80 to 100 mm Hg)
Number of subjects: 248
Study 7475182 — intervention group
Group type: COMPARATOR
Intervention: Low mean arterial pressure (50 to 60 mm Hg)
Number of subjects: 248
Study 2404806 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone supplementation of 100 mg/day, initiated 10 hours before hCG administration and continued for 6 days.
Number of subjects: 52
Study 2404806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no progesterone supplementation).
Number of subjects: 52
Study 2404806 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone supplementation group.
Number of subjects: 52
Study 7370145 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 60 mg
Number of subjects: 72
Study 7370145 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 75 mg
Number of subjects: 72
Study 7370145 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 72
Study 7370145 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 72
Study 30915004 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Family Psychoeducation
Number of subjects: 300
Study 30915004 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Family Psychoeducation
Number of subjects: 300
Study 28148503 — intervention group
Group type: COMPARATOR
Intervention: Traffic Light Labels (TLL)
Number of subjects: 1357
Study 28148503 — intervention group
Group type: COMPARATOR
Intervention: Health Star Rating labels (HSR)
Number of subjects: 1357
Study 28148503 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light Labels (TLL) and Health Star Rating labels (HSR)
Number of subjects: 1357
Study 25867105 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving a small favor from a confederate
Number of subjects: 173
Study 25867105 — intervention group
Group type: COMPARATOR
Intervention: Not receiving a small favor from a confederate
Number of subjects: 173
Study 24946464 — intervention group
Group type: EXPERIMENTAL
Intervention: Perazine
Number of subjects: 58
Study 24946464 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 58
Study 24946464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 58
Study 21191361 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF plus SRL
Number of subjects: 299
Study 21191361 — intervention group
Group type: COMPARATOR
Intervention: MMF/CNI
Number of subjects: 299
Study 19054806 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 103
Study 19054806 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein
Number of subjects: 103
Study 19054806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment
Number of subjects: 103
Study 19054806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment score
Number of subjects: 103